When you come to a stock pick website like this and see a random story that ;predicts a company will have great revenue growth going forward, hey, I get…
treosulfan
Specialty pharmaceuticals is a unique niche in the pharma sector. Where companies like Eli Lilly pour billions into developing a drug candidate from scratch with the very real possibility…
Medexus Pharmaceuticals (MDP.T) has a boatload of pharma IP in the guise of numerous drug treatments that bring in excess of US$100m per year in revenues, which we like…
Medexus Pharmaceuticals (MDP.TO) today announced preliminary estimates of the company’s revenue results for the quarter ended December 31st 2022 (fiscal Q3 2023). After Q2 2023 being Medexus’ strongest quarter…
Specialty pharma company Medexus Pharmaceuticals (MDP.TO) announced today that it plans to host a conference call at 8:00 am EST on Wednesday November 9th 2022. The call will discuss…
Medexus Pharmaceuticals (MDP.TO) is a specialty pharma company. They are not biotech. There is no research and development here. Medexus is all about sales and marketing, bringing over drugs…
15 August 2022
Medexus Pharmaceutical (MDP.T) readies for powerful year of growth in…
Gaalen Engen- MDP.T
Big pharma firms like Abbvie can offer incredible product growth potential to investors, but they also saddle shareholders with tremendous risk in terms of regulatory approval and capital cost….
Medexus Pharmaceuticals (MDP.TO) is a specialty pharma company whose stock is on fire! The stock rallied 34% from its opening price to its highs last week. And it has…
Medexus Pharmaceuticals (MDP.T), a Canadian-based specialty pharma company focused on acquiring and distributing innovative rate disease treatment solutions, announced its financial results for Q1 2023. The company reported a…
Medexus (MDP.T), a Canadian-based specialty pharma firm focused on acquiring and distributing innovative rare disease treatment solutions in North America, announced today that its strategic partner, medac, had resubmitted…